Market capitalization | $232.03m |
Enterprise Value | $277.49m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 16.43 |
P/S ratio (TTM) P/S ratio | 13.74 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 17.91% |
Revenue (TTM) Revenue | $16.89m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
8 Analysts have issued a Inventiva - ADR forecast:
8 Analysts have issued a Inventiva - ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 17 17 |
18%
18%
|
|
Gross Profit | 13 13 |
-
|
|
EBITDA | -110 -110 |
25%
25%
|
EBIT (Operating Income) EBIT | -113 -113 |
26%
26%
|
Net Profit | -113 -113 |
33%
33%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
Head office | France |
CEO | Frédéric Cren |
Employees | 123 |
Founded | 2011 |
Website | www.inventivapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.